A 10-year-old boy presents to the emergency department with his parents. The boy complains of fever, neck stiffness, and drowsiness for the last several days. His past medical history is noncontributory. The boy was born at 39 weeks gestation via spontaneous vaginal delivery. He is up to date on all vaccines and is meeting all developmental milestones. There were no sick contacts at home or at school. The family did not travel out of the area recently. His heart rate is 100/min, respiratory rate is 22/min, blood pressure is 105/65 mm Hg, and temperature is 40.5ºC (104.9°F). On physical examination, he appears unwell and confused. His heart rate is elevated with a regular rhythm and his lungs are clear to auscultation bilaterally. During the examination, he experiences a right-sided focal seizure, which is controlled with lorazepam. A head CT reveals bilateral asymmetrical hypodensities of the temporal region. A lumbar puncture is performed and reveals the following: WBC count 25/mm3 Cell predominance lymphocytes Protein elevated The patient is started on a medication to treat the underlying cause of his symptoms. What is the mechanism of action of this medication?

Nucleoside reverse transcriptase inhibition

Binding with ergosterol in the cell membrane

Gene therapy updates for USMLE Step 2 CK: High-Yield Pediatrics Lessons

Gene Therapy 101 - Fixing Faulty Blueprints

Core Concept: A technique to treat or cure genetic disorders by modifying a person's genes.
Key Strategies:
- Gene Replacement: A functional gene is introduced to replace a mutated one.
- Gene Inactivation: The mutated gene is 'switched off'.
- Gene Editing: Correcting the DNA sequence directly (e.g., CRISPR-Cas9).
Vectors: Modified viruses (Adeno-Associated Virus - AAV, Lentivirus) are the most common delivery vehicles.

⭐ Zolgensma (onasemnogene abeparvovec) is a landmark AAV-based gene therapy for Spinal Muscular Atrophy (SMA), replacing the defective SMN1 gene.

Viral vector gene therapy mechanism

Genetic Mail Carriers - Viral & Non-Viral Vectors

Gene therapy relies on vectors to deliver therapeutic genes into target cells. The choice of vector is critical and depends on the specific application, balancing efficiency against safety.

Viral and Non-Viral Gene Therapy Vectors and Clinical Use

Feature	Viral Vectors	Non-Viral Vectors
Mechanism	Use natural viral ability to infect cells	Chemical or physical methods
Examples	Adeno-associated virus (AAV), Lentivirus, Adenovirus	Liposomes, Nanoparticles, Electroporation
Efficiency	High transduction efficiency	Low to moderate efficiency
Safety Profile	Risk of immunogenicity, insertional mutagenesis	Safer, lower immunogenicity, non-integrating
Cargo Size	Limited capacity	Larger gene capacity

📌 Mnemonic: "All Little Angels" for common viral vectors: AAV, Lentivirus, Adenovirus.

New Cures on Block - Landmark Treatments

Zolgensma (Onasemnogene abeparvovec):
- For Spinal Muscular Atrophy (SMA) Type 1.
- In-vivo therapy using an AAV9 vector to deliver a functional SMN1 gene.
- Notably crosses the blood-brain barrier.
Luxturna (Voretigene neparvovec):
- For Leber's Congenital Amaurosis (LCA) from biallelic RPE65 mutations.
- In-vivo therapy delivered via subretinal injection.
Libmeldy (Atidarsagene autotemcel):
- For early-onset Metachromatic Leukodystrophy (MLD).
- Ex-vivo therapy using a lentiviral vector to insert a functional ARSA gene into patient hematopoietic stem cells (HSCs).
Casgevy (Exagamglogene autotemcel):
- For Sickle Cell Disease & β-thalassemia.
- First approved CRISPR/Cas9-based therapy.
- Ex-vivo editing of HSCs to increase fetal hemoglobin (HbF).

In vivo vs. Ex vivo Gene Therapy with Cas9

⭐ Zolgensma is famed as one of the world's most expensive drugs, with a single dose costing over $2 million. Its one-time administration offers a potential cure for SMA type 1.

CRISPR & Challenges - Editing The Future

CRISPR-Cas9: A revolutionary gene-editing tool. Comprises Cas9 nuclease ("molecular scissors") and a guide RNA (gRNA) to target specific DNA sequences.
Mechanism: Creates double-strand breaks (DSBs) at the target site.
- NHEJ (Non-Homologous End Joining): Inactivates genes (knockout).
- HDR (Homology Directed Repair): Corrects mutations (knock-in).

CRISPR-Cas9 Gene Editing and DNA Repair Pathways

⭐ High-Yield: Exagamglogene autotemcel (Exa-cel/Casgevy) is the first FDA-approved CRISPR therapy. It targets the BCL11A gene to treat Sickle Cell Disease & β-thalassemia by increasing fetal hemoglobin (HbF) production.

Challenges:
- Off-target effects: Unintended DNA cuts.
- Delivery: Efficient in vivo delivery to target cells remains a hurdle.
- Ethical concerns: Particularly regarding germline editing.

High‑Yield Points - ⚡ Biggest Takeaways

Zolgensma (onasemnogene abeparvovec) for Spinal Muscular Atrophy (SMA) uses an AAV9 vector to deliver a functional SMN1 gene.

Luxturna (voretigene neparvovec) is the approved therapy for RPE65 mutation-associated retinal dystrophy.

CAR-T cell therapy (e.g., Kymriah) is a revolutionary treatment for relapsed/refractory B-cell ALL.

Gene therapies for hemoglobinopathies like Thalassemia and Sickle Cell Disease are a key area of research.

Distinguish ex-vivo (CAR-T) from in-vivo (Zolgensma) gene delivery methods.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play